ProMetic was founded in 1994. The scientists at ProMetic Life Sciences are meticulous about proteins. The biotech company develops protein technologies for pharmaceutical, diagnostic, and blood and plasma product development. ProMetic's Protein Technologies division licenses its technologies to companies around the globe, who then make their own products. The company's Therapeutics division conducts proprietary drug development programs for blood disease and cancer therapeutics. The company has collaborative agreements with pharmaceutical companies and health organizations such as Abraxis BioScience, Merck Serono, and The American Red Cross.

Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California. Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin in Phase 3 trial program for the treatment of obesity; APD791, an anti-thrombotic drug candidate, which has completed Phase 1a and Phase 1b clinical trials; and APD125 that is in Phase 2b clinical trial for the treatment of insomnia. The company's clinical development programs also include APD597, an oral GPR119 agonist that is in Phase 1 clinical trial for the treatment of type 2 diabetes; APD916 drug candidate, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. Its drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including constitutively activated receptor technology and melanophore technology.

SomaLogic helps in the hunt for proteins. Its aptamer arrays bind to proteins in such a way that multiple protein targets can be identified at once. Life sciences researchers use the company's arrays to identify proteins related to angiogenesis (the formation of new blood vessels) and inflammation. Data gathered from this work could be used to develop new drugs and diagnostics for a variety of diseases. SomaLogic has partnered with Quest Diagnostics to develop diagnostics that can measure many proteins at once. As part of the arrangement, Quest Diagnostics made a $15 million investment in the company.

Sinclair Pharma can help those with itchy skin or bleeding gums. The specialty pharmaceutical development company acquires oral health and dermatology companies that have already begun developing products and turns them into new lines or line extensions for commercial sale. Its top sellers include Aloclair for mouth ulcers, Decapinol for gingivitis, and Atopiclair for ezcema. It has a sales presence in the UK, France, Italy, Portugal, and Spain, with marketing partners in more than 80 countries. When former CEO Michael Flynn led a management buy-in in 2000, Sinclair's strategy shifted from being a traditional early research and development company to an acquisition vehicle of late-stage development products.

Trius Therapeutics is an early-stage biopharmaceutical company developing antibiotics to treat life-threatening bacterial infections. Torezolid phosphate, its most important drug in development, is an IV- and orally-administered antibiotic with a potential to treat antibiotic-resistant strains of staph infections, known as MRSA (methicillin-resistant Staphylococcus aureus). Until the company is able to sell torezolid phosphate to hospitals and other health care providers, the company is primarily funded by government grants, research contracts, and collaboration agreements. The company filed for an initial public offering in November 2009.

Titan Pharmaceuticals thinks big. The development-stage firm is working on drug treatments for large pharmaceutical markets, including central nervous system disorders like chronic pain, Parkinson's disease, and schizophrenia. On its own, the company is developing Probuphine, which may treat opioid addiction; Probuphine combines an already-approved chemical compound with Titan's continuous-release drug delivery technology called ProNeura. Titan is working with Vanda Pharmaceuticals on late-stage compound Iloperidone, a possible treatment for schizophrenia.

Zila, Inc., a diagnostic company, engages in the prevention, detection, and treatment of oral cancer and periodontal disease. It manufactures and markets ViziLite Plus with TBlue, its flagship product, for early detection of oral abnormalities that could lead to cancer. In addition, the company designs, manufactures, and markets a suite of proprietary products directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler, and a portfolio of oral pharmaceutical products for in-office and home-care use. Further, it had certain technology rights, and the United States and foreign patent rights related to the OraTest, an oral cancer diagnostic product. Zila, Inc. markets and sells its products in the United States and Canada through direct sales force, and internationally through third party distributors. The company was founded in 1980 and is headquartered in Phoenix, Arizona. As of September 18, 2009, Zila, Inc. operates as a subsidiary of Tolmar, Inc.

Don and Lucy Hillestad founded Hillestad Pharmaceuticals USA, Inc. in 1959. Hillestad Pharmaceuticals USA goes natural, producing vitamin, mineral, protein, and herb products from all-natural sources. It also makes prescription and nonprescription vitamin products for dialysis patients under the Dialyvite and Hill*Vite names. In addition, Hillestad offers private-label manufacturing of tablets, powders, cremes, lotions, and liquids for doctors and pharmacies, health food stores, and various national and international companies.

Intercell USA (formerly Iomai) is developing needle-free alternatives to boost your immune system using a transcutaneous method, which delivers vaccines to cells found on the outer layers of the skin. It has a handful of product candidates in development, all in patch form, aimed at preventing seasonal flu and travelers' diarrhea (caused by E. coli, for instance). One of its patches is being funded under a contract from the US Department of Health and Human Services to aid in the treatment of pandemic flu. In 2008 the company was acquired by Austria-based vaccine maker Intercell AG.

Forbes Medi-Tech has an answer for folks wanting to lower their cholesterol by changing their diet. The firm makes Reducol, a dietary supplement ingredient that reduces LDL, the "bad" cholesterol associated with increased risk of heart disease. It sells the ingredient to food and nutritionals companies that incorporate it into their products. Pharmavite uses Reducol in its Cholest-Off supplement, and foodmakers in Europe use it in items such as yogurt, milk, and bread. Until 2008 Forbes Medi-Tech also had a drug development operation, which was testing pharmaceutical candidates to treat high cholesterol and metabolic conditions; however, it has divested those operations to focus on its Reducol business.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.